Iovance Biotherapeutics, Inc. (IOVA)
Largest Insider Buys in Sector
IOVA Stock Price History Chart
IOVA Stock Performance
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or …
Insider Activity of Iovance Biotherapeutics, Inc.
Over the last 12 months, insiders at Iovance Biotherapeutics, Inc. have bought $48.33M and sold $503,000 worth of Iovance Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Iovance Biotherapeutics, Inc. have bought $47.89M and sold $503,000 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rothbaum Wayne P. (director) — $45.75M. MCPEAK MERRILL A (director) — $4.58M. Dukes Iain D. (director) — $292,800.
The last purchase of 5,000,000 shares for transaction amount of $45.75M was made by Rothbaum Wayne P. (director) on 2024‑02‑20.
List of Insider Buy and Sell Transactions, Iovance Biotherapeutics, Inc.
| 2024-11-12 | Sale | director | 50,000 0.0169% | $10.06 | $503,000 | -14.96% | ||
| 2024-02-20 | director | 5M 1.4985% | $9.15 | $45.75M | -12.97% | |||
| 2024-02-20 | director | 250,000 0.0749% | $9.15 | $2.29M | -12.97% | |||
| 2024-02-20 | director | 32,000 0.0096% | $9.15 | $292,800 | -12.97% | |||
| 2023-09-18 | director | 10,000 0.0038% | $5.56 | $55,600 | +43.84% | |||
| 2023-09-15 | director | 5M 2.0294% | $5.30 | $26.5M | +60.34% | |||
| 2022-12-21 | director | 10,000 0.0062% | $6.15 | $61,500 | +5.62% | |||
| 2022-12-02 | director | 10M 5.7676% | $6.50 | $65M | -6.58% | |||
| 2022-11-29 | director | 10,000 0.0062% | $6.31 | $63,100 | +4.32% | |||
| 2022-11-28 | director | 10,000 0.0063% | $6.18 | $61,800 | +7.65% | |||
| 2022-11-28 | Interim CEO & General Counsel | 1,000 0.0006% | $5.98 | $5,980 | +7.65% | |||
| 2022-11-23 | director | 10,000 0.006% | $6.10 | $61,000 | +3.05% | |||
| 2022-06-01 | Interim CEO & General Counsel | 1,000 0.0006% | $6.44 | $6,440 | +22.88% | |||
| 2022-05-31 | 500,000 0.3188% | $6.77 | $3.38M | +15.11% | ||||
| 2022-05-31 | 2,187 0.0014% | $6.79 | $14,850 | +15.11% | ||||
| 2022-05-31 | 10,000 0.0064% | $6.84 | $68,400 | +15.11% | ||||
| 2022-05-31 | 7,500 0.0048% | $6.75 | $50,588 | +15.11% | ||||
| 2018-12-18 | director | 24,000 0.0202% | $8.65 | $207,593 | +114.64% | |||
| 2018-12-13 | director | 20,000 0.0082% | $4.81 | $96,273 | +84.26% | |||
| 2018-12-06 | director | 600,000 0.4993% | $9.86 | $5.92M | +82.46% |
Insider Historical Profitability
| Rothbaum Wayne P. | director | 28067333 9.209% | $8.55 | 6 | 0 | +43.3% |
| MCPEAK MERRILL A | director | 320150 0.105% | $8.55 | 9 | 0 | +33.49% |
| Dukes Iain D. | director | 54000 0.0177% | $8.55 | 3 | 0 | +58.85% |
| Maynard Ryan D | director | 7500 0.0025% | $8.55 | 1 | 1 | +15.11% |
| BRISTOL INVESTMENT FUND LTD | 10 percent owner | 10023628 3.2888% | $8.55 | 1 | 0 |
Institutional Investor Ownership
| The Vanguard Group | $369.24M | 8.9 | 24.92M | +9.22% | +$31.16M | 0.01 | |
| MHR Fund Management | $355.64M | 8.58 | 24M | +20% | +$59.28M | 34.36 | |
| BlackRock | $295.36M | 7.12 | 19.93M | +4.5% | +$12.71M | 0.01 | |
| Perceptive Advisors | $285.63M | 6.89 | 19.27M | +60.88% | +$108.09M | 0.18 | |
| Avoro Capital Advisors Llc | $173.39M | 4.18 | 11.7M | +74.63% | +$74.1M | 2.08 |